Best cytogenetic response to dasatinib
| . | No. (%) of patients . | |
|---|---|---|
| 6 months' follow-up | 8 months' follow-up | |
| CCyR | 21 (58) | 21 (58) |
| PCyR | 0 | 0 |
| Minor cytogenetic response | 1 (3) | 1 (3) |
| Minimal cytogenetic response | 0 | 0 |
| No cytogenetic response | 0 | 0 |
| Not evaluable* | 14 (39) | 14 (39) |
| . | No. (%) of patients . | |
|---|---|---|
| 6 months' follow-up | 8 months' follow-up | |
| CCyR | 21 (58) | 21 (58) |
| PCyR | 0 | 0 |
| Minor cytogenetic response | 1 (3) | 1 (3) |
| Minimal cytogenetic response | 0 | 0 |
| No cytogenetic response | 0 | 0 |
| Not evaluable* | 14 (39) | 14 (39) |
Number of patients in each column was 36.
Not evaluable represents patients who discontinued therapy before the first cytogenetic assessment.